{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:55:06Z","timestamp":1793386506499,"version":"4.5.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We present findings from the multicenter, double-blind Phase 3 study, CENTURION. This study was designed to assess the efficacy of and consistency of response to lasmiditan in the acute treatment of migraine across four attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1:1:1 to one of three treatment groups \u2013 lasmiditan 200 mg; lasmiditan 100 mg; or a control group that received placebo for three attacks and lasmiditan 50 mg for either the third or fourth attack. The primary endpoints were pain freedom at 2\u2009h (first attack) and pain freedom at 2\u2009h in \u22652\/3 attacks. Secondary endpoints included pain relief, sustained pain freedom and disability freedom. Statistical testing used a logistic regression model and graphical methodology to control for multiplicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1471 patients treated \u22651 migraine attack with the study drug. Both primary endpoints were met for lasmiditan 100 mg and 200 mg ( p\u2009&lt;\u20090.001). All gated secondary endpoints were met. The incidence of treatment-emergent adverse events (TEAEs) was highest during the first attack. The most common TEAEs with lasmiditan were dizziness, paresthesia, fatigue, and nausea; these were generally mild or moderate in severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results confirm the early and sustained efficacy of lasmiditan 100 mg and 200 mg and demonstrate consistency of response across multiple attacks. Trial Registration Number: NCT03670810<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0333102421989232","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T02:58:03Z","timestamp":1612839483000},"page":"294-304","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":69,"title":["Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study"],"prefix":"10.1177","volume":"41","author":[{"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[{"name":"Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[{"name":"StudyMetrix Research, St Peters, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Krikke-Workel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R","family":"Klise","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bragg","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin G","family":"Doty","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie A","family":"Dowsett","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krege","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"bibr1-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-004-0064-2"},{"key":"bibr2-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1999.00006.x"},{"key":"bibr3-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828967"},{"key":"bibr4-0333102421989232","unstructured":"European Medical Agency Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products for the treatment of migraine, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf (2007, accessed 29 July 2020)."},{"key":"bibr5-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00404.x"},{"key":"bibr6-0333102421989232","unstructured":"REYVOW\u00ae (lasmiditan) tablets (package insert). Eli Lilly and Company, Indianapolis, IN, http:\/\/pi.lilly.com\/us\/reyvow-uspi.pdf (2019, accessed 31 October 2020)."},{"key":"bibr7-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"bibr8-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"bibr9-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr10-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"bibr11-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"bibr12-0333102421989232","unstructured":"Clinical global impressions. In: Guy W (ed) ECDEU\n                      assessment manual for psychopharmacology \u2013 revised\n                      . Rockville, MD: US Department of Health, Education, and Welfare, 1976, pp.218\u2013222."},{"key":"bibr13-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"bibr14-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419864132"},{"key":"bibr15-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419855080"},{"key":"bibr16-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1111\/head.13731"},{"key":"bibr17-0333102421989232","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102421989232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0333102421989232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102421989232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:22Z","timestamp":1777387762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0333102421989232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/0333102421989232"],"URL":"https:\/\/doi.org\/10.1177\/0333102421989232","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}